Symbols / CPRX Stock $31.35 +0.02% Catalyst Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
CPRX (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Richard John Daly M.B.A.
Exch · Country NCM · United States
Market Cap 3.84B
Enterprise Value 3.08B
Income 221.32M
Sales 596.96M
FCF (ttm) 171.81M
Book/sh 8.29
Cash/sh 6.18
Employees 182
Insider 10d —
IPO Nov 08, 2006
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 18.12
Forward P/E 10.00
PEG —
P/S 6.43
P/B 3.78
P/C —
EV/EBITDA 10.08
EV/Sales 5.16
Quick Ratio 6.70
Current Ratio 7.10
Debt/Eq 0.27
LT Debt/Eq —
EPS (ttm) 1.73
EPS next Y 3.14
EPS Growth 11.10%
Revenue Growth 5.60%
EPS Gr Q/Q 12.30%
Rev Gr Q/Q —
Earnings (next) 2026-08-05
Earnings (prior) 2026-05-11
ROA 16.27%
ROE 24.50%
ROIC —
Gross Margin 84.04%
Oper. Margin 49.02%
Profit Margin 37.08%
Shs Outstand 122.42M
Shs Float 115.58M
Insider Own 5.57%
Instit Own 89.78%
Short Float 8.29%
Short Ratio 2.63
Short Interest 8.19M
52W High 32.56
vs 52W High -3.73%
52W Low 19.05
vs 52W Low 64.54%
Beta 0.74
Impl. Vol. 24.71%
Rel Volume 0.15
Avg Volume 2.11M
Volume 317.08K
Target (mean) $32.60
Tgt Median $32.00
Tgt Low $31.50
Tgt High $36.00
# Analysts 5
Recom Hold
Prev Close $31.34
Price $31.34
Change 0.02%
About

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$32.60
Mean price target
2. Current target
$31.35
Latest analyst target
3. DCF / Fair value
$25.26
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$31.35
Low
$31.50
High
$36.00
Mean
$32.60

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-28 down HC Wainwright & Co. Buy → Neutral $32
2026-05-08 down Citigroup Buy → Neutral $32
2026-05-07 down Stephens & Co. Overweight → Equal-Weight —
2026-03-03 main Citigroup Buy → Buy $35
2025-11-07 main Citigroup Buy → Buy $33
2025-03-03 main Baird Outperform → Outperform $32
2025-02-28 reit HC Wainwright & Co. Buy → Buy $35
2025-02-27 reit Stephens & Co. Overweight → Overweight $33
2025-02-04 init Baird — → Outperform $28
2025-01-10 main HC Wainwright & Co. Buy → Buy $35
2025-01-09 reit B of A Securities Buy → Buy $30
2024-11-18 init Stephens & Co. — → Overweight $35
2024-11-11 main Truist Securities Buy → Buy $36
2024-11-08 reit HC Wainwright & Co. Buy → Buy $30
2024-08-12 main HC Wainwright & Co. Buy → Buy $30
2024-08-09 main Citigroup Buy → Buy $31
2024-08-09 main Truist Securities Buy → Buy $30
2024-06-06 reit Oppenheimer Outperform → Outperform $29
2024-06-03 reit HC Wainwright & Co. Buy → Buy $26
2024-05-10 main HC Wainwright & Co. Buy → Buy $26
News
RSS: Latest CPRX news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-03 ANDREWS WILLIAM T Officer — 3,052 — —
2026-02-17 RUSSO GREGG Officer — 687 — —
2026-01-05 KALB MICHAEL WAYNE Chief Financial Officer — 7,139 — —
2026-01-05 DALY RICHARD J Chief Executive Officer — 42,105 — —
2025-12-29 TIERNEY DAVID S Director — 1,334 — —
2025-12-29 ELSBERND BRIAN D Officer — 6,667 — —
2025-12-29 DEL CARMEN JEFFREY Officer — 8,667 — —
2025-12-29 HARPER MOLLY Director — 1,334 — —
2025-12-29 SUNDARAM PREETHI Officer — 6,667 — —
2025-12-29 MILLER STEVEN R Chief Operating Officer — 14,000 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
588.99
+19.78%
491.73
+23.49%
398.20
+85.90%
214.20
Operating Revenue
588.99
+19.78%
491.73
+23.49%
398.20
+85.90%
214.20
Cost Of Revenue
87.25
+26.74%
68.84
+32.48%
51.97
+51.10%
34.39
Reconciled Cost Of Revenue
86.88
+26.93%
68.45
+32.52%
51.65
+50.80%
34.25
Gross Profit
501.74
+18.64%
422.89
+22.14%
346.24
+92.56%
179.81
Operating Expense
243.96
+7.11%
227.76
-12.20%
259.43
+232.72%
77.97
Research And Development
12.71
+0.48%
12.65
-86.42%
93.15
+370.72%
19.79
Selling General And Administration
193.75
+9.01%
177.74
+32.93%
133.71
+134.23%
57.09
Selling And Marketing Expense
122.24
+9.79%
111.34
+28.44%
86.69
+194.17%
29.47
General And Administrative Expense
71.51
+7.70%
66.40
+41.20%
47.02
+63.76%
28.71
Salaries And Wages
22.57
+10.26%
20.47
+60.33%
12.77
+106.69%
6.18
Other Gand A
48.94
+6.56%
45.92
+34.08%
34.25
+51.99%
22.54
Total Expenses
331.21
+11.67%
296.61
-4.75%
311.39
+177.13%
112.36
Operating Income
257.78
+32.11%
195.12
+124.77%
86.81
-14.75%
101.84
Total Operating Income As Reported
257.78
+32.11%
195.12
+124.77%
86.81
-14.75%
101.84
EBITDA
295.65
+26.94%
232.90
+94.58%
119.69
+16.12%
103.08
Normalized EBITDA
294.68
+29.35%
227.82
+90.34%
119.69
+16.12%
103.08
Reconciled Depreciation
37.87
+0.26%
37.77
+14.88%
32.88
+2553.83%
1.24
EBIT
257.78
+32.11%
195.12
+124.77%
86.81
-14.75%
101.84
Total Unusual Items
0.97
-80.85%
5.08
+67.82%
3.02
—
Total Unusual Items Excluding Goodwill
0.97
-80.85%
5.08
+67.82%
3.02
—
Net Income
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Pretax Income
283.51
+31.10%
216.26
+128.82%
94.51
-9.75%
104.72
Net Non Operating Interest Income Expense
24.77
+54.16%
16.06
+243.61%
4.67
—
Net Interest Income
24.77
+54.16%
16.06
+243.61%
4.67
—
Other Income Expense
0.97
-80.85%
5.08
-34.08%
7.70
+167.23%
2.88
Other Non Operating Income Expenses
—
—
7.70
+167.23%
2.88
Gain On Sale Of Security
0.97
-80.85%
5.08
+67.82%
3.02
—
Tax Provision
69.19
+32.11%
52.37
+126.72%
23.10
+6.75%
21.64
Tax Rate For Calcs
0.00
+0.83%
0.00
-0.82%
0.00
+17.87%
0.00
Tax Effect Of Unusual Items
0.24
-80.69%
1.23
0.00
0.00
Net Income Including Noncontrolling Interests
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Net Income From Continuing Operation Net Minority Interest
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Net Income From Continuing And Discontinued Operation
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Net Income Continuous Operations
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Normalized Income
213.59
+33.46%
160.04
+124.12%
71.41
-14.05%
83.08
Net Income Common Stockholders
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Diluted EPS
1.68
+28.24%
1.31
+107.94%
0.63
-16.00%
0.75
Basic EPS
1.75
+26.81%
1.38
+105.97%
0.67
-16.25%
0.80
Basic Average Shares
122.29
+3.24%
118.46
+11.46%
106.28
+2.81%
103.37
Diluted Average Shares
127.26
+1.85%
124.94
+9.84%
113.75
+2.13%
111.38
Diluted NI Availto Com Stockholders
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Amortization
37.50
+0.32%
37.38
+14.78%
32.56
+2865.85%
1.10
Amortization Of Intangibles Income Statement
37.50
+0.32%
37.38
+14.78%
32.56
+2865.85%
1.10
Depreciation Amortization Depletion Income Statement
37.50
+0.32%
37.38
+14.78%
32.56
+2865.85%
1.10
Depreciation And Amortization In Income Statement
37.50
+0.32%
37.38
+14.78%
32.56
+2865.85%
1.10
Total Other Finance Cost
-24.77
-54.16%
-16.06
-243.61%
-4.67
—
Line Item Trend 2023-12-31
Total Assets
470.11
Current Assets
219.33
Cash Cash Equivalents And Short Term Investments
137.64
Cash And Cash Equivalents
137.64
Other Short Term Investments
—
Receivables
53.65
Accounts Receivable
53.51
Other Receivables
0.14
Accrued Interest Receivable
—
Inventory
15.64
Raw Materials
1.91
Work In Process
4.57
Finished Goods
9.16
Prepaid Assets
12.05
Other Current Assets
0.35
Total Non Current Assets
250.78
Net PPE
3.70
Gross PPE
4.43
Accumulated Depreciation
-0.72
Properties
0.00
Machinery Furniture Equipment
0.93
Other Properties
2.51
Leases
0.99
Goodwill And Other Intangible Assets
194.05
Other Intangible Assets
194.05
Investments And Advances
16.49
Long Term Equity Investment
16.49
Non Current Deferred Assets
36.54
Non Current Deferred Taxes Assets
36.54
Non Current Prepaid Assets
—
Total Liabilities Net Minority Interest
82.23
Current Liabilities
76.06
Payables And Accrued Expenses
66.35
Payables
28.06
Accounts Payable
14.79
Other Payable
12.54
Current Accrued Expenses
38.28
Pensionand Other Post Retirement Benefit Plans Current
8.88
Total Tax Payable
0.73
Income Tax Payable
0.73
Current Debt And Capital Lease Obligation
0.37
Current Capital Lease Obligation
0.37
Other Current Liabilities
0.47
Total Non Current Liabilities Net Minority Interest
6.17
Long Term Debt And Capital Lease Obligation
3.19
Long Term Capital Lease Obligation
3.19
Tradeand Other Payables Non Current
2.50
Other Non Current Liabilities
0.48
Stockholders Equity
387.88
Common Stock Equity
387.88
Capital Stock
0.11
Common Stock
0.11
Preferred Stock
0.00
Share Issued
107.12
Ordinary Shares Number
107.12
Treasury Shares Number
0.00
Additional Paid In Capital
266.49
Retained Earnings
121.27
Gains Losses Not Affecting Retained Earnings
0.01
Other Equity Adjustments
0.01
Total Equity Gross Minority Interest
387.88
Total Capitalization
387.88
Working Capital
143.27
Invested Capital
387.88
Total Debt
3.56
Capital Lease Obligations
3.56
Net Tangible Assets
193.83
Tangible Book Value
193.83
Dueto Related Parties Current
—
Dueto Related Parties Non Current
—
Interest Payable
1.03
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
208.67
-12.98%
239.81
+67.00%
143.60
+23.74%
116.05
Cash Flow From Continuing Operating Activities
208.67
-12.98%
239.81
+67.00%
143.60
+23.74%
116.05
Net Income From Continuing Operations
214.33
+30.78%
163.89
+129.50%
71.41
-14.05%
83.08
Depreciation Amortization Depletion
37.87
+0.26%
37.77
+14.88%
32.88
+2553.83%
1.24
Depreciation
0.38
-5.54%
0.40
+25.63%
0.32
+124.11%
0.14
Amortization Cash Flow
37.50
+0.32%
37.38
+14.78%
32.56
+2865.85%
1.10
Depreciation And Amortization
37.87
+0.26%
37.77
+14.88%
32.88
+2553.83%
1.24
Amortization Of Intangibles
37.50
+0.32%
37.38
+14.78%
32.56
+2865.85%
1.10
Other Non Cash Items
-0.06
+90.13%
-0.56
-100.67%
83.22
+1794.06%
4.39
Stock Based Compensation
24.78
+11.36%
22.25
+56.15%
14.25
+80.22%
7.91
Asset Impairment Charge
0.46
0.00
0.00
—
Deferred Tax
-6.85
+27.05%
-9.39
+47.31%
-17.82
-460.91%
4.94
Deferred Income Tax
-6.85
+27.05%
-9.39
+47.31%
-17.82
-460.91%
4.94
Operating Gains Losses
—
—
0.26
-65.62%
0.76
Gain Loss On Investment Securities
—
—
—
0.76
Unrealized Gain Loss On Investment Securities
-0.97
+80.85%
-5.08
-67.82%
-3.02
0.00
Gain Loss On Sale Of PPE
—
—
0.26
+6.07%
0.25
Change In Working Capital
-60.90
-296.98%
30.91
+182.83%
-37.32
-371.86%
13.73
Change In Receivables
-61.00
-409.96%
-11.96
+72.23%
-43.08
-1027.62%
-3.82
Changes In Account Receivables
-61.00
-409.96%
-11.96
+72.23%
-43.08
-1027.62%
-3.82
Change In Inventory
-18.09
-364.18%
-3.90
+17.77%
-4.74
-544.98%
1.06
Change In Prepaid Assets
-0.18
+97.92%
-8.50
-46.82%
-5.79
-617.72%
-0.81
Change In Payables And Accrued Expense
18.77
-66.26%
55.65
+234.81%
16.62
-5.56%
17.60
Change In Accrued Expense
24.16
-55.13%
53.85
+828.41%
5.80
-64.61%
16.39
Change In Payable
-5.39
-399.83%
1.80
-83.38%
10.82
+796.44%
1.21
Change In Account Payable
-5.39
-399.83%
1.80
-83.38%
10.82
+796.44%
1.21
Change In Other Current Liabilities
-0.40
-8.67%
-0.37
-9.17%
-0.34
-10.10%
-0.31
Investing Cash Flow
-0.06
+89.57%
-0.56
+99.81%
-293.50
-3287.12%
9.21
Cash Flow From Continuing Investing Activities
-0.06
+89.57%
-0.56
+99.81%
-293.50
-3287.12%
9.21
Net PPE Purchase And Sale
-0.06
+89.57%
-0.56
-140.69%
-0.23
-696.55%
-0.03
Purchase Of PPE
-0.06
+89.57%
-0.56
-140.69%
-0.23
-696.55%
-0.03
Capital Expenditure
-0.06
+89.57%
-0.56
+99.32%
-81.74
-281775.86%
-0.03
Net Investment Purchase And Sale
0.00
0.00
+100.00%
-13.46
-169.99%
19.24
Purchase Of Investment
0.00
0.00
+100.00%
-13.46
0.00
Sale Of Investment
—
0.00
0.00
-100.00%
19.24
Net Intangibles Purchase And Sale
0.00
0.00
+100.00%
-81.51
0.00
Purchase Of Intangibles
0.00
0.00
+100.00%
-81.51
0.00
Net Other Investing Changes
—
—
-198.29
-1882.93%
-10.00
Financing Cash Flow
-16.99
-112.08%
140.66
+1395.62%
-10.86
-740.91%
1.69
Cash Flow From Continuing Financing Activities
-16.99
-112.08%
140.66
+1395.62%
-10.86
-740.91%
1.69
Net Common Stock Issuance
-25.30
-117.94%
141.00
0.00
0.00
Common Stock Payments
-25.30
0.00
0.00
0.00
Repurchase Of Capital Stock
-25.30
0.00
0.00
0.00
Proceeds From Stock Option Exercised
14.67
+8.54%
13.52
+384.06%
2.79
-70.82%
9.57
Net Other Financing Charges
-6.36
+54.06%
-13.85
-1.47%
-13.65
-73.32%
-7.88
Changes In Cash
191.62
-49.56%
379.92
+336.33%
-160.76
-226.63%
126.95
Beginning Cash Position
517.55
+276.03%
137.64
-53.87%
298.39
+74.05%
171.44
End Cash Position
709.17
+37.02%
517.55
+276.03%
137.64
-53.87%
298.39
Free Cash Flow
208.61
-12.81%
239.25
+286.79%
61.86
-46.68%
116.02
Interest Paid Supplemental Data
0.47
-66.59%
1.40
+97.87%
0.70
0.00
Income Tax Paid Supplemental Data
71.99
+5.16%
68.45
+35.66%
50.46
+558.12%
7.67
Common Stock Issuance
0.00
-100.00%
141.00
0.00
0.00
Issuance Of Capital Stock
0.00
-100.00%
141.00
0.00
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category